Things aren't looking great for oxycodegol, a potential new pain drug that has been in Nektar Therapeutics' (NASDAQ: NKTR) late-stage pipeline for a long time. The FDA will discuss the slow-acting opioid's benefits in light of its risks with a panel of independent experts on Jan. 14, 2020, and recently released briefing documents prepared for the advisory committee aren't too encouraging.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,